Introduction
============

Atherosclerosis is a highly prevalent disease that can significantly increase the risk of major vascular events, such as myocardial or cerebral infarctions ([@B18]). Atherosclerosis is a multifactorial disease consisting of a multitude of pathogenic developments, including foam cell formation and death, extracellular lipid accumulation, chronic inflammation, and smooth muscle cell proliferation \[*reviewed in* [@B31] and [@B26]\]. There is growing evidence that both chronic inflammation and hyperlipidemia are key risk factors for the development of vascular diseases including atherosclerosis \[*reviewed in* [@B2]\]. Atherosclerotic plaque is usually made of fatty substances (cholesterol, triglycerides, lipoprotein, etc.), it is the main culprit that causes atherosclerosis, and it can partially or completely block the blood flow in the arteries \[*reviewed in* [@B13]\].

A human genome-wide association study has revealed tetratricopeptide repeat domain protein 39B (TTC39B) gene associated with a change in blood lipoprotein levels ([@B35]). The nuclear receptor liver X receptors (LXRs) upregulated a series of genes, including *Abcg5, Abcg8, Abca1*, and so on, which promote coordinated mobilization of excess cholesterol from cells and from the body \[Reviewed in [@B4]\], making it a potentially therapeutic target for the treatment of metabolic and atherosclerotic diseases. [@B15] elucidated the functional association between TTC39B and LXRs and provided evidence that TTC39B deficiency stabilized endogenous LXRs level and its target genes as well as decreased the incidence of atherosclerosis and fatty liver. Furthermore, TTC39B deficiency also inhibited hepatic sterol regulatory element-binding protein 1 (SREBP-1) ([@B15]), which controls lipogenic gene expression \[reviewed in [@B41]\]. Thus, inhibition of T39, and thus stabilization of endogenous LXRs, provided insights into treating metabolic diseases, including atherosclerosis and fatty liver \[reviewed in [@B23] and [@B37]\].

Green tea (*Camellia sinensis*) is an extremely popular beverage worldwide, is next to water, and its habitual consumption has long been associated with health benefits \[*reviewed in* [@B34]\]. Green tea and tea constituents have a potential protective effect against cardiovascular disease that may be due to lowering lipid levels ([@B8]). Among natural compounds of particular interest, (--)-epigallocatechin-3-gallate (EGCG) has gained significant attention in the past decade for its health benefits. EGCG, a major catechin component of green tea, has recently been confirmed to be beneficial effective cardiovascular diseases, including acute and chronic myocardial infarction ([@B7]; [@B20]), ischemic stroke ([@B27]), as well as atherosclerosis ([@B10]). In the clinical atherosclerotic study, EGCG significantly improved endothelial function and improved plasma lipid profile ([@B42]). In experimental studies, drinking water supplemented with EGCG evidently inhibited high-fat-diet (HFD)-induced atherosclerosis in ApoE-knockout (ApoE^-/-^) mice ([@B25]; [@B44]). The salubrious effects of EGCG may be due to its various biological activities, such as anti-oxidative, anti-inflammatory, and hypolipidemic activities ([@B10]). However, the exact mechanism of EGCG on atherosclerosis remains unclear.

Therefore, the aim of the present study was to evaluate whether EGCG treatment modulated (1) high-fat-induced atherosclerosis; (2) inflammatory response and lipid profile in experimental atherosclerotic mice; and (3) TTC39B is involved in EGCG-mediated anti-atherosclerotic activities in experimental atherosclerotic mice.

Materials and Methods {#s1}
=====================

Chemicals and Reagents
----------------------

(--)-Epigallocatechin-3-gallate (≥95%) was purchased from Sigma-Aldrich (Sigma Chemical Co., St. Louis, MO, United States). Total cholesterol (TC), triglycerides (TG), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) assay kits were purchased from Jiancheng Bio-engineering Institute (Nanjing, China). Trizol reagent was obtained from Invitrogen Inc. (Carlsbad, CA, United States), PrimerScript RT Reagent Kit was purchased from Takara Bio (Shiga, Japan), and the quantitative real-time reverse transcription (RT)-polymerase chain reaction (qPCR) kit was purchased from Bio-Rad Laboratories (Hercules, CA, United States). Antibodies against TTC39B (ab107673), LXRα (ab176323), LXRβ (ab28479), and sterol regulatory element-binding transcription factor 1 (SREBP-1) (ab28481) were purchased from Abcam (Cambridge, United Kingdom). Anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH, sc-25778) antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, United States).

Experimental Procedures
-----------------------

Animal experimental protocols used for the study have been approved by the Animal Care and Ethical Use Committee of Hefei Normal University, in accordance to the guidelines for care and use of animals established by the Hefei Normal University. Thirty 7-week-old male ApoE^-/-^ (18--24 g, C57BL/6J background) mice were obtained from Vital River Laboratory Animal Technology Co. Ltd. (Beijing, China). Mice were provided with a standard rodent chow diet and distilled water *ad libitum* and housed at 21 ± 3°C, 60 ± 10% relative humidity, and exposed to 12 h light--12 h dark cycles. After 1-week acclimation, ApoE^-/-^ mice were divided randomly into two groups (*n* = 15 for each group) and were fed with HFD (D12079B, Research Diets, Inc., New Brunswick, NJ, United States^[1](#fn01){ref-type="fn"}^) with or without treatment for 18 weeks as follows: (1) ApoE^-/-^/control group was fed a HFD and (2) ApoE^-/-^/treatment group was fed an HFD and administered EGCG (40 mg/kg/d, i.g.). The dose of EGCG (40 mg/kg/d, i.g.) chose is based on our pre-trial and previous studies ([@B43]; [@B33]). EGCG was dissolved in distilled water and a total volume of 0.1 mL was administered daily. The control group was administered with 0.1 mL distilled water. At the end of the experiment, all mice were euthanized after being food-deprived for 12 h. Plasma was prepared by centrifugation within 15 min after collection at 1,550 × *g* for 20 min at 4°C (Allegra X-30R; Beckman Coulter, Inc., Brea, CA, United States). Liver tissues were quickly dissected and weighed (liver coefficient is determined by the ratio of wet liver weight:body weight). The sample of liver was divided into six parts and placed in a 1.5 mL Eppendorf tube. These plasma and liver samples were then stored at -80°C for further analysis. Aortas were collected from the base of ascending aorta and to the iliac bifurcation, whereas aortic roots with heart were harvested and both are fixed in 4% paraformaldehyde.

Plasma and Hepatic Lipid Parameters
-----------------------------------

Plasma TG, TC, HDL-C, LDL-C, ALT, and AST concentrations were assayed using common commercially available biochemical kits (JianCheng Bioengineering Institute, Nanjing, China). The lipids were extracted from liver tissues as previously described ([@B39]), and then TC and TG levels were determined using plasma TC and TG determination kits.

Atherosclerotic Lesion and Liver Tissue Analysis
------------------------------------------------

For *en face* analysis of the atherosclerotic lesions, the entire aorta was isolated and stained with Oil Red O. Briefly, the entire aorta was dissected and opened longitudinally. After staining with Oil Red O (Sigma-Aldrich; Sigma Chemical Co., St. Louis, MO, United States), *en face* images of the aorta were taken with a dissecting microscope (Motic, China) and analyzed using the ImageJ software (version 1.42q, NIH). The lesion area of each mouse is described as the percentage of total luminal surface. Aortic sinuses and liver tissues were embedded in OCT embedding medium, and cryosections (8 μm) were stained with Oil Red O. Mean lesion area was calculated from 14 consecutive Oil Red O-stained sections per mouse. Images of sections were obtained by a light microscope (Olympus BX41, Tokyo, Japan) and the Oil Red O positive atherosclerotic lesion area was measured using the ImageJ software (version 1.42q, NIH).

Quantitative Real-Time Reverse Transcription-Polymerase Chain Reaction (qPCR)
-----------------------------------------------------------------------------

The mRNA expression levels of *Ttc39b, Lxrα, Lxrβ, Abcg5, Abcg8, Abca1, Srebf1, Scd1, Scd2, Fas, Pnpla3, Acss2, Elovl5, Gpam*, and *Mylip* in liver tissues were detected by qPCR as previously described ([@B40]; [@B39]). The primer information is given in **Table [1](#T1){ref-type="table"}**. Briefly, total RNA from liver tissues was extracted by Trizol and 1 μg of RNA was used to generate cDNA using a PrimerScript RT Reagent Kit (Takara Bio, Shiga, Japan). Reverse transcription (RT) reactions were performed according to the manufacturer's instructions. The qPCR analysis was performed in triplicate for target mRNAs using a qPCR SYBR Green Mix Kit (Bio-Rad Laboratories, Hercules, CA, United States) and the PCR conditions were as follows: 1 cycle of 95°C, 5 min; 40 cycles of 95°C, 15 s; 60°C, 20 s. The fluorescent signals of SYBR Green were subjected to cDNA analysis using an ABI StepOne machine (Applied Biosystems, Forster, CA, United States). Melting curve analysis was performed to confirm specificity. The 2^-ΔΔC~T~^ method was used for the semi-quantitative PCR analysis. Target RNA levels were normalized to GAPDH mRNA.

###### 

SYBR green primer information.

  Gene symbol   Gene name                                                  GenBank Acc. No.   Primer sequences (5′→3′)       *T*~m~ (°C)   *E* (%)   Am (bp)
  ------------- ---------------------------------------------------------- ------------------ ------------------------------ ------------- --------- ---------
  *Ttc39b*      Tetratricopeptide repeat domain 39B                        NM_027238          F: TGAGCCTTTTCAGTGTTCCCT       81.0          95        171
                                                                                              R: CATCCTGGCCTTCCATACCTA                               
  *Lxrα*        Nuclear receptor subfamily 1, group H, member 3            AF085745           F: TGACTCCAACCCTATCCCTAA       82.0          91        141
                                                                                              R: GTTTCTCCTGATTCTGCAACG                               
  *Lxrβ*        Nuclear receptor subfamily 1, group H, member 2            NM_009473          F: GGCGATAAGCAAGGCATACTC       84.0          92        182
                                                                                              R: AAACAGCCAGACGCTACAACC                               
  *Abcg5*       ATP-binding cassette subfamily G member 5                  AH011511           F: CATCTGCCACTTATGATACAGG      84.7          94        236
                                                                                              R: CAGTGATTATGCGTCTCGTTC                               
  *Abcg8*       ATP-binding cassette subfamily G member 8                  AH011518           F: AAGGCTGAGTATCACCAGTCTTGAA   79.4          104       135
                                                                                              R: GGACCTGAACTCGCATCCACT                               
  *Abca1*       ATP-binding cassette subfamily A member 1                  NM_013454          F: GGCAGCATCTTCTTGATTTTGTC     83.4          94        163
                                                                                              R: GAAACCCAATCCCAGATACCC                               
  *Srebf1*      Sterol regulatory element binding transcription factor 1   NM_011480          F: CACTTCGTAGGGTCAGGTTCT       81.4          99        101
                                                                                              R: GCTGAATAAATCTGCTGTCTTG                              
  *Scd1*        Stearoyl-Coenzyme A desaturase 1                           NM_009127          F: CCGTGCCTTGTAAGTTCTGTG       82.3          93        92
                                                                                              R: GCCTCTTCGGGATTTTCTACT                               
  *Scd2*        Stearoyl-Coenzyme A desaturase 2                           NM_009128          F: CGAACCTTTACTGTAGACCCTTG     80.5          99        117
                                                                                              R: TTGTCCCTGATGACCTCGTTT                               
  *Fas*         Fatty acid synthase                                        NM_007988          F: CCGTGGTGCTGGAGATTG          85.4          102       168
                                                                                              R: GGTTGACATTGATGCCTGTGA                               
  *Pnpla3*      Patatin-like phospholipase domain containing 3             NM_054088          F: CAGGGCAGCATGATGTAGGAC       83.1          92        188
                                                                                              R: GAAAATGGCAAACTTGTGGGA                               
  *Acss2*       Acyl-CoA synthetase short-chain family member 2            NM_019811          F: GAAAGTTGTAGCCACATAGAGCATA   83.3          97        231
                                                                                              R: AGCCAGTCCCCACCAGTTAAG                               
  *Elovl5*      ELOVL fatty acid elongase 5                                NM_134255          F: AACATTCCCTTTCCACAGTCT       78.0          94        115
                                                                                              R: TCATCAGTTCAAAACCCCTAG                               
  *Gpam*        Glycerol-3-phosphate acyltransferase, mitochondrial        NM_008149          F: TTCCTTTCCGTCCTGGTGATA       82.8          94        227
                                                                                              R: GAAGATGAAGACAGTGACTTTGGTG                           
  *Mylip*       myosin regulatory light-chain interacting protein          NM_153789          F: GTTTCGGTGATGGCTCGGTAG       83.2          91        220
                                                                                              R: AGAAACTCCTCATTGGGGTCG                               
  *Gapdh*       Glyceraldehyde-3-phosphate dehydrogenase                   NM_001289726       F: AAGAAGGTGGTGAAGCAGG         82.3          92        111
                                                                                              R: GAAGGTGGAAGAGTGGGAGT                                

Flow Cytometry Analysis
-----------------------

Plasma from the mice were harvested for cytokine measurement using a cytometric bead array (CBA) mouse inflammation kit (BD Biosciences, Cat No. 552364) according to the manufacturer's guidelines for detecting interleukin-6 (IL-6), IL-10, monocyte chemotactic protein-1 (MCP-1), interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and IL-12 production, simultaneously. The samples were analyzed using a flow cytometer (BD Accuri C6; BD Biosciences, San Jose, CA, United States) and FCAP Array software (BD version 3.1) was used to create the standard curves for each cytokine and convert the mean fluorescence intensity (MFI) values into corresponding concentrations.

Protein Extraction and Western Blot Analysis
--------------------------------------------

Western blot analyses were performed as previously described ([@B40]; [@B39]). In brief, liver tissues were homogenized in ice-cold Tris buffer (0.01 M Tris, pH 7.4) and then lysed in extraction buffer with protease and phosphatase inhibitor cocktails (Beyotime Institute of Biotechnology, Haimen, China). Proteins of liver tissues were separated by electrophoresis in a 10% SDS-polyacrylamide gel, and then were transferred onto a PVDF membrane (Millipore, Shanghai, China). Blots were first incubated with an antibody against TTC39B (1:200), LXRα (1:1000), LXRβ (1:1000), SREBP-1 (1:1000), or GAPDH (1:200) overnight at 4°C. After primary antibody incubation, the membranes were washed three times in washing buffer for 10 min each and then incubated with the respective horseradish peroxidase-conjugated secondary antibodies (1:5000; Thermo Fisher Scientific, MA, United States) for 1 h at room temperature. Immunoreactive bands were visualized via the enhanced chemiluminescence (Pierce, Rockford, IL, United States) and quantified via densitometry using ImageJ (version 1.42q, NIH).

Statistical Analysis
--------------------

In this study, all statistical analyses were conducted using SPSS 13.0 (SPSS, Chicago, IL, United States) and a two-tailed independent sample *t*-tests or a Mann--Whitney *U*-test as indicated for the comparison of the two groups. Experimental data are expressed as the means ± SEM, and *P* \< 0.05 was considered statistically significant.

Results
=======

EGCG Attenuated Atherosclerotic Plaque Development in ApoE^-/-^ Mice
--------------------------------------------------------------------

As shown in **Figure [1A](#F1){ref-type="fig"}**, *en face* analysis revealed that atherosclerotic plaques (Oil Red O-stained red area) in the artery formed was observed in high-fat-fed ApoE^-/-^ mice. Intriguingly, EGCG treatment with 40 mg/kg/d significantly reduced the size of Oil Red O-stained atherosclerotic plaques in the aortas (**Figure [1B](#F1){ref-type="fig"}**). Atherosclerotic burden was further evaluated in cross-sections of the aortic root. Treatment with EGCG (40 mg/kg/d) significantly decreased the lesion area in the aortic root (**Figures [1C,D](#F1){ref-type="fig"}**). During the entire experimental period, no mice died (data not shown).

![EGCG attenuated atherosclerotic plaque development in ApoE^-/-^ mice. Illustration of ApoE^-/-^ mice were fed with HFD and were treated daily with or without EGCG for 18 weeks by oral gavage. Morphology and quantification of atherosclerotic plaques in the whole aorta **(A,B)** and aortic sinus (magnification, ×40) **(C,D)**. ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001 compared with high-fat-fed ApoE^-/-^ mice (*n* = 8).](fphar-09-00195-g001){#F1}

EGCG Altered Plasma Lipid Profile and Hepatic Lipid Metabolism in ApoE^-^*^/^*^-^ Mice
--------------------------------------------------------------------------------------

ApoE^-/-^ mice develop hypercholesterolemia and complex atherosclerotic plaques that closely mimic human lesions. Initial body weights were similar between vehicle- and EGCG-treated ApoE**^-/-^** mice (data not shown), whereas treatment with EGCG for 18 weeks observed lower body weights compared to that of ApoE**^-/-^** mice (**Figure [2A](#F2){ref-type="fig"}**). There were no statistically significant differences in food intake between the two groups (**Figure [2B](#F2){ref-type="fig"}**). Meanwhile, plasma lipid profiles were determined in ApoE**^-/-^** mice at the end of 18-week feeding period. As expected, EGCG treatment also dramatically increased HDL-C levels and decreased TC and LDL-C levels in HFD-fed ApoE^-/-^ mice, but has little effect on TG (**Figure [2C](#F2){ref-type="fig"}**). The liver is the main organ for lipid metabolism. Because EGCG treatment improved the plasma lipid profile, we next determined whether EGCG administration affected the hepatic lipid metabolism. The results showed that compared with control ApoE**^-/-^** mice, supplemented with EGCG significantly decreased liver weight (**Figure [2D](#F2){ref-type="fig"}**), liver coefficient (**Figure [2E](#F2){ref-type="fig"}**), TC, and TG content in the liver (**Figure [2F](#F2){ref-type="fig"}**). The similar profile was further confirmed by Oil Red O staining that EGCG significantly inhibited high-fat-fed-induced hepatic lipid accumulation (**Figure [2G](#F2){ref-type="fig"}**). Furthermore, EGCG administration also markedly attenuated HFD-induced liver injury in mice (ALT/AST) (**Figure [2H](#F2){ref-type="fig"}**). These results indicated that EGCG supplementation modulated the lipid disorders in HFD-fed ApoE**^-/-^** mice.

![EGCG altered plasma lipid profile and hepatic lipid metabolism in ApoE^-^*^/^*^-^ mice. ApoE^-/-^ mice were fed with HFD and were treated daily with or without EGCG for 18 weeks by oral gavage, body weights, plasma lipid profile, and transaminase levels, and hepatic lipid accumulation was analyzed as described in the section "Materials and Methods." **(A)** Bar graph showed the quantitative analysis of body weights (*n* = 15). **(B)** Bar graph showed the quantitative analysis of food consumption (*n* = 15). **(C)** Bar graph showed the quantitative analysis of TC, TG, LDL-C, and HDL-C levels in plasma (*n* = 15). Bar graph showed the quantitative analysis of liver weight **(D)** and liver coefficient **(E)** (*n* = 15). **(F)** Quantification of hepatic TC and TG levels (*n* = 15). **(G)** Morphology of hepatic lipid accumulation (magnification, ×200, *n* = 6). **(H)** Quantification of plasma AST and ALT activities (*n* = 15). ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001 compared with high-fat-fed ApoE^-^*^/^*^-^ mice.](fphar-09-00195-g002){#F2}

EGCG Modulated TTC39B Expression and Its Target Gene in ApoE^-^*^/^*^-^ Mice
----------------------------------------------------------------------------

To further explore the molecular mechanisms by which EGCG exerted anti-atherosclerotic activity, we examined the effects of EGCG on hepatic TTC39B expression, which modulated lipid metabolism and reduced the process of atherosclerosis ([@B15]). In this experiment, the mRNA and protein levels of hepatic TTC39B in atherosclerotic mice were analyzed by qRCR and western blot, respectively. Intriguingly, treatment with EGCG (40 mg/kg/d) significantly decreased the mRNA and protein levels of hepatic TTC39B in atherosclerotic mice (**Figures [3A](#F3){ref-type="fig"}--[C](#F3){ref-type="fig"}**). In addition, EGCG administration also markedly increased the expression of hepatic LXRβ and inhibited hepatic SREBP-1 expression at both protein and mRNA levels, but only increased LXRα expression at protein level in high-fat-fed ApoE**^-/-^** mice. Moreover, a decrease of mature SREBP-1 expression was also observed in EGCG-treated ApoE**^-/-^** mice. We subsequently examined the effect of EGCG in LXR target gene expression in hepatic tissue by qPCR. As shown in **Figure [3A](#F3){ref-type="fig"}**, EGCG treatment significantly induced *Abcg5, Abcg8*, and *Abca1* mRNA levels and decreased the *Scd1, Scd2, Fas, Elovl5*, and *Mylip* mRNA levels. However, there was no changes in *Pnpla3, Acss2*, and *Gpam* mRNA levels following EGCG treatment (**Figure [3A](#F3){ref-type="fig"}**).

![EGCG modulated TTC39B expression and its target gene in ApoE^-^*^/^*^-^ mice. ApoE^-/-^ mice were fed with HFD and were treated daily with or without EGCG for 18 weeks by oral gavage, the protein, or/and mRNA levels of TTC3B, and target genes in liver were detected as described in the section "Materials and Methods." **(A)** Quantitative analysis of mRNA levels of hepatic *Ttc39b, Lxrα, Lxrβ, Abcg5, Abcg8, Abca1, Srebf1, Scd1, Scd2, Fas, Pnpla3, Acss2, Elovl5, Gpam*, and *Mylip* (*n* = 10). Mann--Whitney *U*-test, ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 compared with high-fat-fed ApoE^-^*^/^*^-^ mice. **(B)** Representative bands of hepatic TTC39B, LXRα, LXRβ, precursor, and mature SREBP-1 protein expression (*n* = 3). **(C)** Quantitative analysis of hepatic TTC39B, LXRα, LXRβ, precursor, and mature SREBP-1 protein levels (*n* = 3). ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 compared with high-fat-fed ApoE^-^*^/^*^-^ mice. See **Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}** for original images.](fphar-09-00195-g003){#F3}

EGCG Suppressed Systemic Inflammation in ApoE^-^*^/^*^-^ Mice
-------------------------------------------------------------

In addition to modulating lipid metabolism, activation of LXR has been demonstrated to inhibit the inflammatory response in ApoE**^-/-^** mice ([@B3]; [@B14]). Next, we explored the effects of EGCG treatment on chronic systemic inflammation by using a CBA. The results revealed that among the six examined cytokines (TNF-α, MCP-1, IFN-γ, IL-6, IL-12, and IL-10), EGCG markedly reduced the production of TNF-α and IL-6 and increased the level of IL-10, whereas the concentrations of the other three cytokines were not significantly influenced by EGCG (**Figure [4](#F4){ref-type="fig"}**).

![EGCG suppressed systemic inflammation in ApoE^-^*^/^*^-^ mice. ApoE^-/-^ mice were fed with HFD and were treated daily with or without EGCG for 18 weeks by oral gavage, plasma cytokines were detected as described in the section "Materials and Methods." **(A,B)** Representative flow cytometry of plasma cytokines. **(C)** Quantification of levels of plasma cytokines. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 compared with high-fat-fed ApoE^-/-^ mice (*n* = 15).](fphar-09-00195-g004){#F4}

Discussion
==========

Historically, consumption of green tea has been associated with health benefits against multiple cardiovascular diseases, including atherosclerosis ([@B1]; [@B16]; [@B21]). In the present study, we uncovered a novel mechanism by which EGCG, a major ingredient of green tea, attenuated atherosclerotic plaque formation by modulated system inflammation and dyslipidemia possibly in a TTC39B-dependent manner.

Dyslipidemia, associated with atherosclerosis, consists of a reduction of HDL-cholesterol and an increase in plasma LDL and TG \[reviewed in [@B9]\]. EGCG is a polyphenolic compound abundant in green tea and several studies reported the relationship between EGCG consumption and the level of blood lipoprotein \[reviewed in [@B19]\]. For instance, EGCG treatment reduced serum concentrations of TC and TG in *db*/*db* mice or high-fat diabetic mice ([@B1]; [@B28]). Consistent with previous reports, we found that EGCG significantly modulated plasma lipid disorder and hepatic lipid accumulation, which accompanied by reduction of atherosclerotic plaque in high-fat-fed ApoE^-/-^ mice. However, supplemented with EGCG (10 mg/kg) through daily intraperitoneal injections significantly reduced aortic plaque formation in hypercholesterolemic ApoE^-/-^ mice, but no difference was observed in plasma TC level ([@B6]). Similarly, drinking water supplemented with green tea extract attenuated the development of atherosclerosis without changing the plasma TC or TG level in ApoE^-/-^ mice ([@B25]). Different drug delivery and higher dose used may explain the different hypolipidemic effects observed. Firstly, we chose to use EGCG (40 mg/kg) through daily gavage instead of intraperitoneal injections or administration in the drinking water. In addition, when it is orally administrated, EGCG is mainly absorbed in intestine, and gut microbiota plays a pivotal role in its metabolism prior to absorption and is essential for the absorption of its metabolites (such as gallic acid and epigallocatechin) \[reviewed in [@B12]\]. EGCG supplementation prevented HFD-induced alterations in gut microbiota, such as *Firmicutes/Bacteroidetes* ratio and microbial diversity ([@B29]). Changes in gut microbiota composition due to different dietary feeding might be relevant for several chronic conditions, including atherosclerosis ([@B32]). Finally, EGCG administration in drinking water was easily oxidized and unstable for 24 h ([@B25]). TTC39B is a novel potential therapeutic target for treating both steatohepatitis and atherosclerosis ([@B15]). TTC39B deficiency displayed increased HDL-cholesterol levels associated with increased enterocyte *Abca1* expression, increased LXR protein, decreased fatty liver, decreased LDL levels, and reduced atherosclerosis ([@B15]). Thus, the study led us to hypothesize that EGCG attenuated high-fat-mediated atherosclerosis at least partially through modulation of TTC39B, an HDL gene discovered in human genome-wide association studies ([@B35]). In support of this, we found that EGCG administration significantly reduced hepatic TTC39B expression at both mRNA and protein levels in high-fat-fed ApoE^-/-^ mice. LXRs are oxysterol-activated nuclear receptors and the primary function of LXRs is thought to be cholesterol homeostasis through upregulation of target genes, including *Abcg5, Abcg8, Abca1*, and so on, which mediate cellular cholesterol efflux \[reviewed in [@B11]\]. Due to its ability to enhance ABCA1-dependent reverse cholesterol transport, LXR is an attractive target for the treatment of atherosclerosis ([@B17]). TTC39B can promote the ubiquitination and degradation of LXR. Conversely, TTC39B deficiency stabilizes LXR protein without change in LXR mRNA ([@B15]). Consistent with these findings, EGCG-treated ApoE^-/-^ mice displayed decreased TTC39B levels at both mRNA and protein levels associated with increased hepatic LXRβ at both mRNA and protein levels and increased LXRα protein expression, accompanied by reduction of hepatic lipid accumulation and atherosclerotic plaque. However, the precise mechanism of EGCG on hepatic LXRs mRNA expression remains to be clarified. At the same time, SREBP-1 is the master regulator of *de novo* fatty acid biosynthesis and implicated in hepatic steatosis through upregulation of expression of many lipogenic genes, including *Scd1* and *Elovl5*, leading to elevated plasma and liver TC levels ([@B17]). In the present study, EGCG-treated ApoE^-/-^ mice also had significant reductions in hepatic precursor and mature of SREBP-1 expression and *Srebf1* mRNA expression, and this effect was associated with a decrease of lipogenic gene *Scd1, Scd2, Fas, Elovl5*, and *Mylip* mRNA expression. In addition, LXRα-dependent increase in phosphatidylcholine synthesis and incorporation of polyunsaturated fatty acids into multiple phospholipid species which further inhibited hepatic SREBP-1 expression ([@B15]). Collectively, our data suggested that the downregulation of TTC39B by EGCG preserved LXRα and LXRβ expression associated with downregulation of SREBP-1 expression, eventually activated a beneficial profile of gene expression that promotes hypolipidemic effects. However, the precise mechanisms of TTC39B in EGCG-mediated vasculoprotection has not been fully elucidated. This mechanism could be particularly valuable to clarify the role of EGCG in modulation of dyslipidemia.

Vascular chronic inflammation is one of the key early events in the pathogenesis of atherosclerosis ([@B22]; [@B2]). Dietary supplementation of EGCG counteracted several adverse effects associated with vascular inflammation and atherosclerosis, including decreased secretion of inflammatory cytokines such as IL-6 and TNF-α ([@B1]; [@B30]). In addition, EGCG attenuated inflammation, lipid uptake, and intracellular cholesterol accumulation in macrophages ([@B5]; [@B38]). Therefore, antioxidant and anti-inflammatory activities of EGCG were responsible for its protective effects against atherosclerosis ([@B6]; [@B7]; [@B34]; [@B20]; [@B5]). Consistent with previous reports ([@B6]), high-fat-fed ApoE^-/-^ mice presented with both significantly smaller aortic atheromatous area and aortic sinus plaque when treatment with EGCG through intragastric administration. In addition, EGCG also significantly inhibited high-fat-mediated system inflammation, evidencing by the decrease of IL-6 and TNF-α and increase of IL-10. Increased IL-10 levels may create an anti-inflammatory environment and lead to protection against atherosclerosis development ([@B24]; [@B36]). We chose to use EGCG (daily 40 mg/kg) intragastric administration, which ensure that the plasma level of EGCG was adequate ([@B25]; [@B6]). With the amount of EGCG administered, there were significantly higher anti-inflammatory and anti-atherogenic capacities both in the systemic circulation and in local vascular tissue. Mechanistically, activation of LXRs upregulates a suite of genes that promote coordinated mobilization of excess cholesterol from cells and from the body \[reviewed in [@B4]\]. Moreover, LXRs, like other nuclear receptors, are anti-inflammatory, inhibiting signal-dependent induction of pro-inflammatory genes by nuclear factor-κB, activating protein-1, and other transcription factors \[reviewed in [@B11]\]. Consistent with this notion, EGCG treatment significantly reduced TTC39B expression and enhanced LXRα expression, with that of *Abca1* and *Abcg5/8* also being increased. Activation of the LXRα-ABCA1/ABCG5/8 pathway exerted anti-inflammatory and lipid-regulatory effects during atherosclerosis \[reviewed in [@B11]\]. Therefore, reduction of TTC39B and enhancement of the LXRα-ABCA1/ABCG5/8 pathway was at least partly responsible for the inhibitory effect of EGCG on the anti-inflammatory and lipid-regulatory effects in high-fat-induced atherosclerosis.

The major new finding of the present study was that EGCG, a major ingredient of green tea, modulated high-fat-mediated hepatic TTC39B expression, which were responsible for lipid metabolism disorder in ApoE^-/-^ mice. Meanwhile, our results also demonstrated that EGCG administration attenuated the formation of atherosclerotic plaque and system chronic inflammatory processes in atherosclerotic mice. Therefore, our data suggested that EGCG ingestion might have therapeutic potential in the prevention of atherosclerosis.
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